{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-001744","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2026-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.362594+00:00","generated_at":"2026-05-15T12:33:16.581061+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Xenetic Biosciences reports 2025 net loss $2.7M, cash $7.9M, advances DNase program","bullets":["Net loss $2.7M for FY2025; royalty revenue from Takeda sublicense rose 19% to $3.0M.","R&D expenses decreased 7% to $3.1M (excl. prior-year impairment); G&A down 20% to $2.7M.","Ended year with $7.9M cash, up $1.7M from prior year-end, aided by $4.0M October public offering.","Preclinical data supporting DNase I for NETs in cancers; progressing toward IND submission.","Pursuing strategic alternatives to maximize shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-001744","json":"https://secwatch.observer/filing/0001683168-26-001744.json","markdown":"https://secwatch.observer/filing/0001683168-26-001744.md","text":"https://secwatch.observer/filing/0001683168-26-001744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826001744/0001683168-26-001744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826001744/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:33:16.581061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d4d2384f7991430c87f74105d55dc6a1f07b291b","claim":"Xenetic Biosciences, Inc. reported the year ended December 31, 2025 results: revenue $3.0 million, net income approximately $2.7 million.","evidence_excerpt":"investment in the Company’s most promising scientific programs. Royalty revenue from the Company’s sublicense with Takeda Pharmaceuticals Co. Ltd increased approximately 19% to $3.0 million in the year ended December 31, 2025 from $2.5 million for the year ended December 31, 2024 primarily due to royalty payments received from certain countries. Research and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826001744/0001683168-26-001744-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Revenue","value":"$3.0 million"},{"label":"Net income","value":"approximately $2.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}